WHEN A CURE BECOMES A KILLER: LESSONS FROM INDIA'S RECENT COUGH SYRUP TRAGEDY : DR. DAREKAR



Dr. Avinash Darekar
Principal- KVN Naik Pharmacy College Nashik.

In early October 2025, India was rocked by a new pharmaceutical scandal: multiple deaths of young childrenlargely in Madhya Pradesh were linked to consumption of a cough syrup brand named Coldrif, manufactured by Sresan Pharmaceutical, containing extremely high levels of diethylene glycol (DEG). Lab reports suggest the DEG content was nearly 500 times above permissible limits. The tragedy quickly spiraled into a multi-state regulatory and criminal investigation. This is not the first time that contaminated cough syrups have caused fatalities in India or abroad past incidents in The Gambia, Uzbekistan, and Cameroon linked to Indian-made products had already raised red flags. But the high visibility and domestic impact of this latest case bring into sharper focus crucial technical, legal, and ethical lessons especially for pharmacists, regulatory professionals, and students. Below I dissect the key technical failures, regulatory/legal fallout, industry consequences (national & international), and the moral lessons for pharmacy professionals and students.

TECHNICAL & QUALITY CONTROL FAILURES: WHERE THE SYSTEM BROKE DOWN

a) Contaminated Excipients & Solvent Substitution

One of the recurring themes in DEG/ethylene glycol poisoning is the substitution (sometimes intentional, sometimes unintentional) of pharmaceutical-grade glycols or solvents with cheaper industrial-grade substitutes contaminated with DEG/ethylene glycol. If proper raw-material checks, certificates of analysis, and supplier audits are lacking, cost pressures may drive such compromises.

b) Inadequate In-Process and Finished Product Testing

The tragedy suggests that the manufacturer either did not test for DEG/EG as a part of its quality control (QC) panel or the QC checks were superficial or manipulated. Regulatory statements indicate "serious lapses" at pharmaceutical firms, failure to test every batch, or non-compliance with batch release norms. In oral liquids (especially pediatric syrups), the margin for error is extremely narrow even trace contamination can be catastrophic.

c) Weak Post-Market Surveillance and Feedback Loops

By the time the cluster of deaths surfaced, the contaminated batches had already been widely distributed, consumed, and possibly exported (or at least travelled across state lines). That indicates a weakness in pharmacovigilance (adverse events linked to medicines), batch traceability, recall mechanisms, and rapid response to "signals."

d) Lab Capacity, Chain of Custody & Testing Mismatch

Some regulatory bodies have pointed out inconsistencies between field samples and central lab results, highlighting gaps in chain-of-custody, sampling integrity, inter-laboratory reproducibility and standardization of methods. Also, different states may rely on different labs with varying capabilities and standards, introducing risk of conflicting outcomes.

REGULATORY & LEGAL FALL OUT: ACCOUNTABILITY, RISK & REFORM

Statutory Violations & Criminal Liability

Under India's Drugs & Cosmetics Act, 1940 and associated rules, adulteration or misbranding that endangers health is an offense. If proven, sections relating to adulterated drugs (Section 27), manufacturing without licence or violating manufacturing norms (Section 18, 17), and causing death by negligence or culpable homicide may come into play. In this case, the owner of Sresan Pharma has already been arrested, and FIRs have been filed. But proving causation (i.e. that a particular batch caused a particular death) requires strong forensic and toxicological evidence, chain-of-custody of samples, matching batch numbers, and expert testimony. The legal process may be long and contested.

Licensure Suspension, Recall & Market Bans

Regulators have banned the implicated cough syrups, ordered recall of stocks, suspended operations of the implicated units, and banned sales in multiple states. Some state regulators are now inspecting all liquid oral formulations in their jurisdictions. The central drug regulator (CDSCO) is under pressure to review and tighten standards, approve only stronger testing regimes, mandate DEG/EG testing for all oral liquids, and coordinate state-level enforcement.

Reputational Risk, Export Controls & International Liability

India brands itself as the "pharmacy of the world," supplying generics and bulk APIs to many countries. A scandal of this magnitude undermines international trust, may invite stricter import inspections, import bans, or blacklisting of Indian exporters in some markets. There may even be civil claims in foreign courts by affected families or governments, if export links are established. Past cases in Gambia (70 children died) and Uzbekistan have already seen serious diplomatic and legal ramifications.

Regulatory Overhaul & Systemic Reform

This incident is likely to accelerate regulatory reform: mandating more rigorous national pharmacopoeial standards, independent third-party lab validations, stricter audits of raw material suppliers, more robust central-state coordination, better pharmacovigilance, and possibly legislative amendments to raise penalties for pharmaceutical misconduct.

BROADER INDUSTRY AND INTERNATIONAL CONSEQUENCES

Loss of Public Trust: Patients, prescribers, and regulators may grow skeptical of Indian generics and oral liquid formulations. Even non-implicated companies may suffer trust erosion.

Export Barriers : Countries importing Indian medicines may impose extra testing, audits, or certifications (e.g. "DEG-free certificate") before accepting consignments, increasing cost barriers.Increased

Regulatory Costs : Manufacturers will have to invest more in quality systems, raw-material audits, more frequent, sensitive testing, documentation, and stricter traceability raising production costs and margins.

Consolidation & Exit of Weak Players : Companies unable to bear the increased compliance burden may shut down or merge; weaker players may exit the market, raising industry concentration.

Insurance, Liability & Litigation Exposure: Pharmaceutical manufacturers may become more exposed to product liability lawsuits, requiring better insurance, legal defense, and corporate risk management.

Global Scrutiny & Compliance Alignment : Indian firms seeking to compete globally will be forced to upgrade to the highest global standards (ICH, WHO GMP, etc.), aligning with global regulatory expectations to prevent reputational damage.

KEY TAKEAWAYS & MORAL LESSONS FOR PHARMACY STUDENTS AND PROFESSIONALS

A. Quality Isn't Optional It's Foundational

No matter how well the therapeutic design is, a medicine is only as safe as its weakest raw material or process control. In critical dosage forms, such as pediatric syrups, rigorous QC for every batch is non-negotiable.

B. Ethics Over Profit Pressure

The temptation to cut costs by sourcing cheaper inputs or skimping on tests must be resisted. The moral cost of harming (or killing) children outweighs short-term economic gain.

C. Pharmacovigilance is a Duty, Not a Form

Be alert to adverse event signals, especially in pediatrics. Pharmacists and clinicians are the frontline eyes. Early detection and reporting of unusual clusters (e.g. unexplained renal failure in children) can prevent more tragedy.

D. Traceability, Documentation & Audit Trails Matter

Maintain impeccable records, batch-level traceability, chain-of-custody for samples, and ready audit documentation. In litigation or regulatory review, these become your evidence.

E. Continuous Learning & Regulatory Awareness

Students and professionals must stay updated with evolving regulatory norms, scientific toxicology (e.g. DEG/EG risks), and recent scandals not as blames but as lessons.

F. Whistleblower Courage & Internal Checks

Professionals in manufacturing or quality units may sometimes spot red flags. A system that allows safe reporting (internal audits, escalations) must be protected.

G. Patient Safety is the Core of Pharmaceutical Profession

Ultimately, our duty is to the patient. Every decision formulation, sourcing, labeling must pass the test: "Does this uphold safety and efficacy for the end user?"

LESSON & CALL TO ACTION

The recent tragedy is a stark reminder: in pharmaceuticals, errors are not mere business risks they are potential loss of life. The regulatory cracks, if unsealed, can turn trusted medicines into silent killers.For pharmacy students, this underscores why your training in pharmaceutics, quality assurance, regulatory science, toxicology, and ethics is not academic it may one day be lifesaving. For professionals and regulators, the incident must galvanize deeper reform, not just reactive bans.If India is to retain its stature as a pharmaceutical powerhouse, it must earn and re-earn trust by embedding uncompromising quality, accountability, and a safety-first culture in every formulation, every batch, and every actor in the chain.